National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings, 47156-47157 [2024-11973]
Download as PDF
<![CDATA[
47156
Federal Register / Vol. 89, No. 106 / Friday, May 31, 2024 / Notices
recommendations on the policies,
programs, and resources required to
address the disparities and inequities in
infant mortality, related adverse birth
outcomes and maternal health
outcomes, including maternal mortality
and severe maternal morbidity. With its
focus on underlying causes of the
disparities and inequities seen in birth
outcomes for women and infants, the
Committee advises the Secretary of
Health and Human Services on the
health, social, economic, and
environmental factors contributing to
the inequities and proposes structural,
policy, and/or systems level changes.
The agenda for the June 26–27, 2024,
meeting is being finalized and may
include the following topics: Federal
updates, including on the Healthy Start
program; maternal and infant mental
health; presentations and Committee
discussions on the workgroup topics of
rural health care access, social drivers of
health, and women’s health before/
between pregnancies; and discussion of
possible recommendations to achieve
optimal maternal health and overall
birth outcomes for underserved
populations, including Black/AfricanAmerican families. Agenda items are
subject to change as priorities dictate.
Refer to the ACIMM website listed
above for any updated information
concerning the meeting.
khammond on DSKJM1Z7X2PROD with NOTICES
Members of the public will have the
opportunity to provide written or oral
comments. Public participants may
submit written statements in advance of
the scheduled meeting by emailing
SACIM@hrsa.gov. Oral comments will
be honored in the order they are
requested and may be limited as time
allows. Requests to submit a written
statement or make oral comments to
ACIMM should be sent to Vanessa Lee,
Designated Federal Official, using the
email address above at least 3 business
days prior to the meeting.
Individuals who plan to attend and
need special assistance or another
reasonable accommodation should
notify Vanessa Lee at the contact
information listed above at least 10
business days prior to the meeting.
Since this meeting occurs in a Federal
Government building, attendees joining
in person must go through a security
check to enter the building. Non-U.S.
Citizen attendees must notify HRSA of
their planned attendance at least 20
business days prior to the meeting to
facilitate their entry into the building.
All attendees are required to present
VerDate Sep<11>2014
17:22 May 30, 2024
Jkt 262001
government-issued identification prior
to entry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Maria G. Button,
Director, Executive Secretariat.
National Institutes of Health
[FR Doc. 2024–11968 Filed 5–30–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; URGenT: Translational
Efforts to Advance Gene-based Therapies for
Ultra-Rare Neurological and Neuromuscular
Disorders.
Date: June 27, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Mirela Milescu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH/DHHS, NSC, 6001 Executive
Boulevard, Rockville, MD 20852, 301–496–
5720, mirela.milescu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS).
Dated: May 24, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–11970 Filed 5–30–24; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NSD–A/B Member Conflict
SEP.
Date: June 24, 2024.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Surojeet Sengupta, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH/DHHS, NSC, 6001 Executive
Boulevard, Room 5134 Rockville, MD 20852,
301–496–9223, surojeet.sengupta@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Validation of Biomarkers.
Date: June 25, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Surojeet Sengupta, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH/DHHS, NSC, 6001 Executive
Boulevard, Room 5134, Rockville, MD 20852,
301–496–9223, surojeet.sengupta@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS).
E:\FR\FM\31MYN1.SGM
31MYN1
Federal Register / Vol. 89, No. 106 / Friday, May 31, 2024 / Notices
Dated: May 24, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–11973 Filed 5–30–24; 8:45 am]
National Institute on Drug Abuse;
Notice of Closed Meetings
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Long-Acting Drug Delivery
Systems for ART Optimization in Children
Living with HIV–1 II (LADDS II) (R61/R33
Clinical Trial Not Allowed).
Date: June 27, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Rockville, MD
20892 (Video Assisted Meeting).
Contact Person: Poonam Pegu, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, MSC–9823,
Rockville, MD 20892, 240–292–0719,
poonam.pegu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 24, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–11981 Filed 5–30–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:22 May 30, 2024
Jkt 262001
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIH
Support for Conferences and Scientific
Meetings (R13).
Date: June 27, 2024.
Time: 1:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Meysam Yazdankhah,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 402–
6965, meysam.yazdankhah@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research.
Date: June 27, 2024.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sudhirkumar U.
Yanpallewar, M.D. Scientific Review Officer
Scientific Review Branch National Institute
on Drug Abuse, NIH 301 North Stonestreet
Avenue, MSC 6021 Bethesda, MD 20892
(301) 443–4577 sudhirkumar.yanpallewar@
nih.gov
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Adolescent Overdose Prevention and SUD
Treatment Initiative.
Date: July 11, 2024.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
47157
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D. Scientific Review Officer
Scientific Review Branch National Institute
on Drug Abuse, NIH 301 North Stonestreet
Avenue, MSC 6021 Bethesda, MD 20892
(301) 443–4577 caitlin.moyer@nih.gov
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: May 24, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–11980 Filed 5–30–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Automated Commercial Environment
(ACE) Export Manifest for Vessel
Cargo Test: Renewal of Test
U.S. Customs and Border
Protection; Department of Homeland
Security.
ACTION: General notice.
AGENCY:
This notice announces that
U.S. Customs and Border Protection
(CBP) is renewing the Automated
Commercial Environment (ACE) Export
Manifest for Vessel Cargo Test, a
National Customs Automation Program
(NCAP) test concerning ACE export
manifest capability.
DATES: The voluntary pilot initially
began on August 20, 2015, as corrected
on October 20, 2015, and modified and
extended on August 14, 2017, and
further extended on April 27, 2022. This
renewal is effective May 31, 2024. The
renewed test will run for an additional
two years from the date of publication
of this notice in the Federal Register.
ADDRESSES: Applications for new
participants in the ACE Export Manifest
for Vessel Cargo Test must be submitted
via email to CBP Export Manifest at
cbpexportmanifest@cbp.dhs.gov. In the
subject line of the email, please write
‘‘ACE Export Manifest for Vessel Cargo
Test Application’’. Applications will be
accepted at any time during the test
period. Written comments concerning
program, policy, and technical issues
may also be submitted via email to CBP
Export Manifest at cbpexportmanifest@
cbp.dhs.gov. In the subject line of the
email, please write ‘‘Comment on ACE
Export Manifest for Vessel Cargo Test’’.
SUMMARY:
E:\FR\FM\31MYN1.SGM
31MYN1
]]>Agencies
[Federal Register Volume 89, Number 106 (Friday, May 31, 2024)]
[Notices]
[Pages 47156-47157]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11973]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; NSD-A/B Member Conflict SEP.
Date: June 24, 2024.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Surojeet Sengupta, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH/DHHS, NSC, 6001 Executive Boulevard, Room 5134
Rockville, MD 20852, 301-496-9223, [email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Validation of Biomarkers.
Date: June 25, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Surojeet Sengupta, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH/DHHS, NSC, 6001 Executive Boulevard, Room
5134, Rockville, MD 20852, 301-496-9223, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS).
[[Page 47157]]
Dated: May 24, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-11973 Filed 5-30-24; 8:45 am]
BILLING CODE 4140-01-P
